WO2007009683A3 - Pharmaceutical formulations of substituted pyrazoline compounds - Google Patents

Pharmaceutical formulations of substituted pyrazoline compounds Download PDF

Info

Publication number
WO2007009683A3
WO2007009683A3 PCT/EP2006/006957 EP2006006957W WO2007009683A3 WO 2007009683 A3 WO2007009683 A3 WO 2007009683A3 EP 2006006957 W EP2006006957 W EP 2006006957W WO 2007009683 A3 WO2007009683 A3 WO 2007009683A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazoline compounds
substituted pyrazoline
pharmaceutical formulations
formulation
parenteral
Prior art date
Application number
PCT/EP2006/006957
Other languages
French (fr)
Other versions
WO2007009683A2 (en
Inventor
Helmut H Buschmann
Original Assignee
Esteve Labor Dr
Helmut H Buschmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384017A external-priority patent/EP1743638A1/en
Application filed by Esteve Labor Dr, Helmut H Buschmann filed Critical Esteve Labor Dr
Publication of WO2007009683A2 publication Critical patent/WO2007009683A2/en
Publication of WO2007009683A3 publication Critical patent/WO2007009683A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the use of substituted pyrazoline compounds characterized in that the pharmaceutical formulation is in the form selected from: • An oral osmotically driven system for the release of the compound • A parenteral implant • A Multipore tablet • A Transdermal application system • A parenteral depotsystem • An oral formulation using a sweet tastemasker with a natural flavour or • A chewable formulation, preferably a chewing gum.
PCT/EP2006/006957 2005-07-15 2006-07-15 Pharmaceutical formulations of substituted pyrazoline compounds WO2007009683A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60/705,456 2005-07-15
EP05384017A EP1743638A1 (en) 2005-07-15 2005-07-15 Pharmaceutical formulations of substituted pyrazoline compounds
EP05384017.9 2005-07-15
US70545605P 2005-08-05 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007009683A2 WO2007009683A2 (en) 2007-01-25
WO2007009683A3 true WO2007009683A3 (en) 2007-04-26

Family

ID=37546625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006957 WO2007009683A2 (en) 2005-07-15 2006-07-15 Pharmaceutical formulations of substituted pyrazoline compounds

Country Status (2)

Country Link
ES (1) ES2330716B1 (en)
WO (1) WO2007009683A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
EP0360562A2 (en) * 1988-09-19 1990-03-28 Edward Mendell Co., Inc. Directly compressible sustained release excipient
EP0581676A2 (en) * 1992-07-30 1994-02-02 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5340849A (en) * 1988-10-03 1994-08-23 Atrix Laboratories, Inc. Biodegradable in-situ forming implants and methods for producing the same
WO1998031227A1 (en) * 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
EP1083171A1 (en) * 1998-05-29 2001-03-14 Laboratorios Del Dr. Esteve, S.A. Pyrazoline derivatives, their preparation and application as medicaments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556568A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
EP0360562A2 (en) * 1988-09-19 1990-03-28 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5340849A (en) * 1988-10-03 1994-08-23 Atrix Laboratories, Inc. Biodegradable in-situ forming implants and methods for producing the same
EP0581676A2 (en) * 1992-07-30 1994-02-02 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
WO1998031227A1 (en) * 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
EP1083171A1 (en) * 1998-05-29 2001-03-14 Laboratorios Del Dr. Esteve, S.A. Pyrazoline derivatives, their preparation and application as medicaments

Also Published As

Publication number Publication date
WO2007009683A2 (en) 2007-01-25
ES2330716A1 (en) 2009-12-14
ES2330716B1 (en) 2010-07-09

Similar Documents

Publication Publication Date Title
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2006127738A3 (en) Compressible chewing gums for delivery of actives
HK1197195A1 (en) Flavoring of drug-containing chewing gums
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
EP1974722A3 (en) Modified dosage forms of tacrolimus
WO2009115178A3 (en) Gingival wafer
WO2005065318A3 (en) Effervescent oral opiate dosage form
WO2009037319A3 (en) Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
WO2006042034A8 (en) Salt and crystalline forms thereof of a drug
WO2007048220A3 (en) Trazodone composition for once a day adminisitiation
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
EP1576986A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
NO20074933L (en) Pharmaceutical composition comprising an indolylmaleimide derivative
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
PL1800669T3 (en) Orodispersible pharmaceutical composition for oral, oromucosal or sublingual administration of agomelatine
WO2008001325A3 (en) Herbal compositions for the treatment of diseases of the oral cavity
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2008060546A3 (en) Oral formulations
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
WO2009060064A3 (en) Pharmaceutical formulations for the oral administration of ppi
WO2007009683A3 (en) Pharmaceutical formulations of substituted pyrazoline compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 200850005

Country of ref document: ES

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06776255

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 200850005

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 200850005

Country of ref document: ES

Kind code of ref document: A